Der Chirurg

, Volume 78, Issue 12, pp 1111–1116

Peritoneal metastasiertes Ovarialkarzinom

Vorgehensweise und Behandlungsergebnisse
Leitthema
  • 103 Downloads

Zusammenfassung

Das Ovarialkarzinom ist der gynäkologische Tumor mit der höchsten Mortalität. Der interdisziplinären chirurgischen Therapie fällt ein hoher Stellenwert zu. In letzter Zeit hat es zahlreiche neue Erkenntnisse über den Stellenwert und Umfang der operativen Therapie dieser Erkrankung gegeben. Die Umsetzung dieser in nationalen und internationalen Standards und Leitlinien implementierten neuen Entwicklungen in den klinischen Alltag ist zur Verbesserung der Situation der Betroffenen dringend erforderlich.

Schlüsselwörter

Ovarialkarzinom Operation Peritonealkarzinose Chemotherapie 

Peritoneal carcinomatosis in ovarian cancer

Methods and treatment results

Abstract

Epithelial ovarian cancer is the gynecological tumor with the highest mortality rate. Numerous findings have recently emerged about the value and extent of surgical therapy of this disease. Already applied to national and international standards and guidelines, these new developments must become part of clinical practice if patients are to benefit.

Keywords

Chemotherapy Ovarian cancer Peritoneal carcinomatosis Surgery 

Literatur

  1. 1.
    Aletti GD, Dowdy SC, Gostout BS et al. (2006) Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol 107: 77–85PubMedGoogle Scholar
  2. 2.
    Armstrong DK, Bundy B, Wenzel L et al. (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354: 34–43PubMedCrossRefGoogle Scholar
  3. 3.
    Bristow RE, Tomacruz RS, Armstrong DK et al. (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20: 1248–1259PubMedCrossRefGoogle Scholar
  4. 4.
    Cliby W, Dowdy S, Feitoza SS et al. (2004) Diaphragm resection for ovarian cancer: technique and short-term complications. Gynecol Oncol 94: 655–660PubMedCrossRefGoogle Scholar
  5. 5.
    du Bois A, Rochon J, Lamparter C, Pfisterer J (2005) Ovarialkarzinom – Versorgungsstruktur und -qualität in Deutschland 2001–2004. Frauenarzt 46: 560–567Google Scholar
  6. 6.
    Eisenhauer EL, Abu-Rustum NR, Sonoda Y et al. (2006) The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol 103: 1083–1090PubMedCrossRefGoogle Scholar
  7. 7.
    Eisenkop SM, Spirtos NM (2001) What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer? Gynecol Oncol 82: 489–497PubMedCrossRefGoogle Scholar
  8. 8.
    Elit L, Chartier C, Oza A et al. (2006) Outcomes for systemic therapy in women with ovarian cancer. Gynecol Oncol 103: 554–558PubMedCrossRefGoogle Scholar
  9. 9.
    Estes JM, Leath CA 3rd, Straughn JM Jr et al. (2006) Bowel resection at the time of primary debulking for epithelial ovarian carcinoma: outcomes in patients treated with platinum and taxane-based chemotherapy. J Am Coll Surg 203: 527–532PubMedCrossRefGoogle Scholar
  10. 10.
    Fanning J, Hilgers RD (1995) Loop electrosurgical excision procedure for intensified cytoreduction of ovarian cancer. Gynecol Oncol 57: 188–190PubMedCrossRefGoogle Scholar
  11. 11.
    Hoffman MS, Griffin D, Tebes S et al. (2005) Sites of bowel resected to achieve optimal ovarian cancer cytoreduction: implications regarding surgical management. Am J Obstet Gynecol 193: 582–586PubMedCrossRefGoogle Scholar
  12. 12.
    Kommission Ovar der AGO (2007) Interdisziplinäre S2k-Leitlinie für die Diagnostik und Therapie maligner Ovarialtumoren. Zuckschwerdt, GermeringGoogle Scholar
  13. 13.
    Piso P, Dahlke MH, Loss M, Schlitt HJ (2004) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer. World J Surg Oncol 2: 21PubMedCrossRefGoogle Scholar
  14. 14.
    Rose PG (1992) The cavitational ultrasonic surgical aspirator for cytoreduction in advanced ovarian cancer. Am J Obstet Gynecol 166: 843–846PubMedGoogle Scholar
  15. 15.
    Rose PG, Nerenstone S, Brady MF et al. Gynecologic Oncology Group (2004) Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 351: 2489–2497PubMedCrossRefGoogle Scholar
  16. 16.
    Tebes SJ, Cardosi R, Hoffman MS (2006) Colorectal resection in patients with ovarian and primary peritoneal carcinoma. Am J Obstet Gynecol 195: 585–589PubMedCrossRefGoogle Scholar
  17. 17.
    Burg ME van der, Lent M van, Buyse M et al. (1995) The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 332: 629–634PubMedCrossRefGoogle Scholar
  18. 18.
    Walker JL, Armstrong DK, Huang HQ et al. (2006) Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 100: 27–32PubMedCrossRefGoogle Scholar
  19. 19.
    Wenzel LB, Huang HQ, Armstrong DK et al. (2007) Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25: 437–443PubMedCrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag 2007

Authors and Affiliations

  • J. Pfisterer
    • 1
  • P. Harter
    • 2
  • F. Hilpert
    • 1
  • A. du Bois
    • 2
  1. 1.Klinik für Gynäkologie und GeburtshilfeUniversitätsklinikum Schleswig-Holstein, Campus KielKielDeutschland
  2. 2.Klinik für Gynäkologie und Gynäkologische OnkologieDr. Horst Schmidt Klinik (HSK)WiesbadenDeutschland

Personalised recommendations